Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netupitant/Palonosetron for Nausea and Vomiting in Germ Cell Tumours
NCT07662200Phase 1Not yet recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of netupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Feasibility of study at 1 year. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
netupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07662200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662200.